###begin article-title 0
###xml 109 115 <span type="species:ncbi:9103">Turkey</span>
Familial Mediterranean Fever: A Retrospective Clinical and Molecular Study in the East of Anatolia Region of Turkey
###end article-title 0
###begin p 1
###xml 207 213 <span type="species:ncbi:9103">Turkey</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 551 558 <span type="species:ncbi:9606">patient</span>
###xml 740 747 <span type="species:ncbi:9606">patient</span>
###xml 888 894 <span type="species:ncbi:9103">Turkey</span>
Familial Mediterranean Fever (FMF) is an autoinflammatory periodic disorder. We aim to identify the distribution and the frequency of the Mediterranean Fever (MEFV) gene mutations in the east of Anatolia in Turkey and perform a genotype/phenotype correlation in the patients' cohort. The study was carried out on 415 clinically diagnosed Turkish FMF patients and 103 healthy controls. The tested individuals were screened for the most common twelve MEFV mutations. The most important features were the predominance of the M694V and E148Q mutations in patient group and the earlier of onset of the disease in M694V mutation carriers compared with the carriers of other mutations (P=0.00). We discuss the high frequency of E148Q mutations in patient group compared with controls, genetic counseling in intermarriage families and the variations in mutation frequency according to regions of Turkey.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3"> 3</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R3">3</xref>
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 881 882 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
Despite its striking symptom pattern, Familial Mediterranean Fever (FMF; MIM# 249100), was first described as a distinct entity in 1945 [1]. FMF, the most frequent hereditary recurrent fever, is an autosomal recessive disease that affects commonly populations of Armenian, Arab, Sephardic Jewish or Turkish origin and it is not uncommon in other Mediterranean populations, such as Italians, Spanish, Portuguese, French, and Greeks [2, 3]. The historic trace-back of the shared haplotype and common mutations suggests a common ancestor at least 2000 years ago, when most of these populations were living together in the eastern Mediterranean basin, around Mesopotamia [3-6]. The carrier frequency of MEFV mutations is quite high in the 4 classically affected populations, ranging from 37-39% in Armenians and Iraqi Jews to 20% in Turks, North African and Ashkenazi Jews, and Arabs [1].
###end p 4
###begin p 5
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R7"> 7</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6"> 6</xref>
###xml 807 838 807 838 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="http://fmf.igh.cnrs.fr/infevers">http://fmf.igh.cnrs.fr/infevers</uri>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R2">2</xref>
###xml 922 924 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5"> 5</xref>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6"> 6</xref>
###xml 1017 1018 1017 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R8">8</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 1147 1150 1147 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11"> 11</xref>
Although an unexplained clinical heterogeneity is not uncommon, the diagnosis of the disease, which is based on various sets of clinical criteria [2, 7], can be confirmed by molecular means that provides the only objective diagnostic criterion in the absence of functional test. In 1997 the gene linked to FMF, called MEFV, was cloned from to chromosome 16p using positional cloning and some of the mutations associated with the disease were identified [1, 6]. The gene comprises 10 exons, spanning approximately 15 kb of genomic DNA and encodes a 781 amino acid-long protein. All four of the initial FMF-associated mutations in MEFV were in exon 10, and even now, with over 55 mutations having been identified (see the Infevers database of FMF and hereditary autoinflammatory disorders mutations online at http://fmf.igh.cnrs.fr/infevers), exon 10 remains the major site of mutations, with a smaller cluster in exon 2 [2, 5, 6]. Nearly all of the known FMF-associated mutations encode conservative missense changes [8-10]. The most frequent mutations (M 680 I, M 694 V, V726 A, M 694 I and E 148 Q) are found in more than two thirds of cases [10, 11].
###end p 5
###begin p 6
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R12">12</xref>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via </italic>
###xml 462 464 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R13">13</xref>
###xml 465 467 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R15">15</xref>
###xml 546 547 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 548 550 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R5"> 5</xref>
###xml 551 553 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6"> 6</xref>
The protein encoded by the MEFV gene, termed pyrin or marenostrin, includes a PYRIN domain (PYD), which has been already analyzed crystallographically [12]. Pyrin presumably participates in a complex interplay with the PYD protein superfamily, lipopolysaccharide (LPS) via Toll-like receptor family and procaspase-1 activation, and is implicated in the homeostatic control of inflammation through leukocyte apoptosis, IL-1beta, and NF-kappaB pathway activation [13-15]. However, the precise function of the entire pyrin protein is still unknown [1, 5, 6].
###end p 6
###begin p 7
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">16</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R16">16</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R18">18</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 400 403 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R19"> 19</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R17">17</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R20">20</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
Molecular analysis of MEFV is a useful tool in clinical practice, mainly in the atypical forms of the disease [16]. However, many clinically typical FMF patients are heterozygous or no disease-associated mutations are found [16-18]. The incomplete penetrance and the varying expression of FMF suggest the presence of other, possibly genetic, factors that could influence the expression of illness [4, 19]. Colchicine is the preferred drug for FMF [17]. Genotype-phenotype correlation, thoroughly studied over the past few years, suggested that mutations located within the mutational hotspots in codons 680 and 694 are associated with severe disease, early onset, high frequency of attacks, the necessity of a high dose of colchicine to control attacks, and frequent occurrence of amyloidosis in untreated patients [20].
###end p 7
###begin p 8
###xml 112 118 <span type="species:ncbi:9103">Turkey</span>
###xml 196 202 <span type="species:ncbi:9103">Turkey</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
The present study aim to investigate the twelve most common MEFV mutations frequency in the east of Anatolia in Turkey and to compared these results with the studies performed in other regions of Turkey, in order to provide a link which will facilitate the clinical interpretation of individualized genetic data and to evaluate the phenotypic features of Turkish FMF patients with the E148Q mutation in homozygous, heterozygous, and complex states in order to shed light on the clinical presentation of this mutation compared with healthy subjects.
###end p 8
###begin title 9
MATERIALS AND METHODOLOGY
###end title 9
###begin title 10
###xml 17 25 <span type="species:ncbi:9606">Patients</span>
Study Design and Patients
###end title 10
###begin p 11
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
###xml 30 35 <span type="species:ncbi:9606">Human</span>
###xml 124 130 <span type="species:ncbi:9103">Turkey</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 395 401 <span type="species:ncbi:9103">Turkey</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1312 1320 <span type="species:ncbi:9606">patients</span>
###xml 1617 1625 <span type="species:ncbi:9606">patients</span>
The study was approved by the Human Studies Ethics Committee of Firat University Hospital in the east of Anatolia region of Turkey. Clinical data on these patients were obtained from the records of Firat University Hospital. All patients were obtained at the Pediatric Clinic and Rheumatology Clinic of Firat University Hospital and a number of medical centers in the east of Anatolia region on Turkey. Diagnosis of FMF patients was established according to previously described criteria [11]. All of them were interviewed directly by one of clinicians with identical clinical forms. These included patients meeting clinical criteria for FMF who desired genetic confirmation of the diagnosis; individuals with unexplained fever, abdominal pain, or arthritis atypical of FMF who were seeking a diagnosis; and several asymptomatic relatives of patients. The diagnosis of FMF was based on a typical clinical picture of recurrent attacks of fever and pain affecting patients, and involving one or two of the following sites at a time: abdomen, chest, joints, muscles, scrotum, and skin. In addition, an increase in acute phase reactants during the attacks, a positive history among siblings or in the extended family, and a good response to colchicine helped to establish the diagnosis. We viewed the records of all patients and looked at the following details: family origin; age of onset; clinical features (fever, abdominal, thoracic, articular, skin, muscular, testicular, and miscellaneous manifestations); severity of the disease by number of attacks per month and duration of attack. The study group included 1100 patients, who were clinically suspected as FMF and 103 healthy controls.
###end p 11
###begin title 12
Genetic Testing
###end title 12
###begin p 13
###xml 126 129 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 513 515 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21">21</xref>
2 ml blood samples were collected from all subjects. Genomic DNA was extracted from whole blood by means of the Promega Wizard(R) Genomic DNA Purification Kit (Promega, USA). Twelve common MEFV gene mutations located in exon 2 (E148Q), exon 3 (P369S), exon 5 (F479L), and exon 10 [M680I (G/C), M680I (G/A), I692del, M694V, M694I, K695R, V726A, A744S, and R761H] were studied with a reverse hybridization assay as described by the manufacturer (FMF Strip Assay; Vienna Lab Labordiagnostika GmbH, Vienna, Austria) [21].
###end p 13
###begin p 14
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R1">1</xref>
###xml 442 445 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R22"> 22</xref>
103 unrelated population-matched healthy controls were enrolled in the study for detection M694V, V726A, M680I, E148Q, M694I, P369S, A744S and R761H mutation rate. Mutation identification in healtly controls was performed according to previously described techniques. The mutations were assessed by amplifying the genomic DNA template with amplification refractory mutation system (ARMS) or restriction fragment length polymorphism (RFLP) [1, 22].
###end p 14
###begin title 15
Genetic Counseling
###end title 15
###begin p 16
###xml 192 200 <span type="species:ncbi:9606">children</span>
Genetic counseling was given by counselors who have, besides their training in genetics, substantial experience in an FMF clinic. We aim to identify couples who are at risk of giving birth to children affected with FMF disease.
###end p 16
###begin title 17
Statistical Analysis
###end title 17
###begin p 18
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
Data were analyzed using the SPSS program (SPSS Inc, Chicago, IL, USA). Comparisons among groups of patients with different combination of mutations in diagnosed FMF patients clinically and mutation anlysis were done by analysis of variance. Categorical variables were compared by using the x2 test. Differences between the proportion of patients with diagnosed FMF and the proportion with ethnicaly mathod healthy control populations were compared statisticaly by the two tailed Fisher's exact test.
###end p 18
###begin title 19
RESULTS
###end title 19
###begin p 20
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 209 210 209 210 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T1">1</xref></bold>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
The analysis of clinical features showed classical patterns. The majority of the patients had fever and abdominal pain during attacks, less frequently thoracic pain and arthritis and rarely amyloidosis. Table 1 summarizes clinical symptoms of 415 patients. The majority of patients experienced an increase of the frequency and intensity of attacks following a stressing event (324/430, 75.3%).
###end p 20
###begin p 21
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">children</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">children</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
415 of 1100 patients suspected as FMF were diagnosed as having FMF according to Yalcinkaya et al. [11]. Of these 415 patients, 251 were males and 179 were females; 268 were adult patients and 162 were children. 64 (23.8%) adults patients were married to their relatives and the parents of 21(12.9%) children patients were relative.
###end p 21
###begin p 22
###xml 811 812 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 811 812 811 812 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T2">2</xref></bold>
###xml 820 821 820 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 820 821 820 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T3">3</xref></bold>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
###xml 1092 1099 <span type="species:ncbi:9606">patient</span>
###xml 1169 1177 <span type="species:ncbi:9606">patients</span>
Among the 586 of 1100 patients, 10.2% (60/586) were homozygotes, 30.8% (181/586) compound heterozygotes and 58.8% (345/586) heterozygotes. No mutation was found in the remaining 514 of FMF patients. It was not found the clinical findings in 51.5% (178/345) of heterozygotes mutation carrier patients. Seven of 415 clinically FMF patients did not found any mutation. But, we detected clinical features in addition to high fibrinogen and CRP levels in patients serum during attacks in seven patients with negative mutation analysis result. These patients were only the carrier for MEFV gene mutation without clinical symptoms. The detected mutations were mainly M694V, V726A, M680I and E148Q. The only rare ones were K695R, M694I and F479L. The distribution of FMF mutations in the study groups is given in Table 2. Table 3 showed the mutation results of 415 patients with one and more mutations for determine the general mutation profile in the east of Anatolia. The most common mutation in patients group was M694V, followed by E148Q, V726A and M680I. We did not detect a I692del mutation in patient group. A familial history of the disease was noticed in 56.3% of the patients and the females/males ratio was estimated to 1.4 (251/179).
###end p 22
###begin p 23
###xml 87 95 <span type="species:ncbi:9606">patients</span>
We assessed the relations between all mutations and clinical characteristic in 415 FMF patients. The mean age of onset of the disease was the lower in M694V mutation carrier (9.3 years) compared with other mutations carriers (13.2 years) (P = 0.00) by Mann-Whitney U test. However, It was not detected any association between other clinical characteristics and the specific mutations.
###end p 23
###begin p 24
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 616 624 <span type="species:ncbi:9606">patients</span>
###xml 673 679 <span type="species:ncbi:76720">fisher</span>
In the healthy controls group, mutation analysis showed that 24 (23.3%) of the subjects were carrying at least one mutated MEFV allele. The frequencies of E148Q, M694V, M694I, V726A and P369S mutation carriage were 12.6% (with 13/206 allele frequency), 5.8% (6/206), 1.9% (2/206), 1.9% (2/206) and 0.9% (1/206), respectively. The distribution of the eight most common mutations among healthy individulas was significantly different from that found in patients. The overall allele frequency calculated from the mutation frequencies in the healthy controls was 12% for E148Q. Compared with healthy controls (12%), FMF patients (19.1%) showed high E148Q allele frequencies by fisher's exact test (p = 0.001).
###end p 24
###begin p 25
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
E148Q mutation was detected in 159 patients, 37 patients were compound heterozygous and 123 patients were heterozygous. It was clinically diagnosed FMF in 25 of 37 compound heterozygous for E148Q mutation, eighteen were carrying E148Q/M694V, three were carrying E148Q/P369S, one was carrying E148Q/V726A, one was carrying E148Q/M680I, E148Q/K695R, and one was carrying E148Q/M680I. One was carrying E148Q/P369S/A744S of 123 heterozygotes patients for E148Q carrier.
###end p 25
###begin p 26
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
Genetic counseling was given all patients with homozygous, heterozygous, complex states or negative result. We advice to get genetic test done the siblings of patients with homozygous, compound homozygous, heterozygous mutation carrier and clinically diagnosed FMF and thirty two patients with second and third degree or more distant relatives to make marriage.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 501 504 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11"> 11</xref>
###xml 505 508 505 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21"> 21</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R30">30</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
###xml 490 496 <span type="species:ncbi:9103">Turkey</span>
In the present study, we report the frequencies of the twelve most common MEFV mutations among Turkish FMF patients in the east of Anatolia region and the phenotype/ genotype correlations in those FMF patients. This is the first study reporting MEFV gene mutation profile in the east of Anatolia and significant evidence for the undefined mutations in patients with E148Q mutation carrier. Our results are in agreement with the most frequent four mutations from the other study groups from Turkey [10, 11, 21-30].
###end p 28
###begin p 29
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R31">31</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 386 387 386 387 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T2">2</xref></bold>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 1040 1043 1040 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11"> 11</xref>
###xml 1044 1047 1044 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R21"> 21</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R30">30</xref>
###xml 112 118 <span type="species:ncbi:9103">Turkey</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 693 701 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
###xml 870 876 <span type="species:ncbi:9103">Turkey</span>
In the studies by Touitou et al. [4], and by the Turkish FMF study group [31], the most common MEFV mutation in Turkey is M694V (57.0 and 51.4%, respectively), followed by M680I (16.5 and 14.4%, respectively), and V726A (13.9 and 8.6%, respectively). Evaluating other studies in Turkish population, carrier rates for four common MEFV gene mutations may appear to vary regionally (Table 2). Range of the frequencies of four common mutations in FMF patients were 15.6-67.2% for M694V, 1.5-14% for V726A, 1.5-19.8% for M680I, for 3.2-30.8% for E148Q. Frequencies in our study were within the previously reported range. Possible explanations for the divergent frequencies of mutation rates in FMF patients may be population, geographical, environmental or genetic heterogeneities, patients' inclusion criteria, methodological detection problems. In 12 population studies in Turkey, the mutations were genetically analyzed with many different techniques: sequencing, PCR-FLP, multiplex PCR, PCR-ELISA, reverse hybridization, ARMS, DGGE etc. [10, 11, 21-30].
###end p 29
###begin p 30
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 101 102 101 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T3">3</xref></bold>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9"> 9</xref>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R32"> 32</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R35">35</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R31">31</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R11">11</xref>
###xml 429 432 429 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R36"> 36</xref>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R37">37</xref>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 910 911 910 911 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="T1">1</xref></bold>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
The M694V mutation was the most common one (21.8%) of the tested alleles in this cohort study (Table 3), as it was already reported in Turkish population and other populations [4, 9, 32-35]. The Turkish FMF study group demonstrated the close relationship between the M694V mutation and the severity of disease [31]. Some studies reported that the highest severity scores were observed in patients carrying the M694V mutation [11, 36]. Tunca et al. reported that patients with the M694V/M694V genotype were found to have an earlier age of onset and higher frequencies of arthritis and arthralgia compared with the other genotypes [37]. This study reveals an association between the earlier of the onset of the disease and the presence of mutation in codon 694 of exon 10. But, we did not detect any association between the other clinical characteristics, such as diseases severity, attack frequency etc. (Table 1) and the specific mutations or genotypes.
###end p 30
###begin p 31
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9"> 9</xref>
###xml 507 510 507 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10"> 10</xref>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R38">38</xref>
###xml 574 577 574 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R39"> 39</xref>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R39">39</xref>
###xml 826 827 826 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R6">6</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R9"> 9</xref>
###xml 831 834 831 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R39"> 39</xref>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R10">10</xref>
###xml 1121 1126 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1265 1267 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R40">40</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 1004 1012 <span type="species:ncbi:9606">patients</span>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
###xml 1192 1200 <span type="species:ncbi:9606">patients</span>
###xml 1342 1350 <span type="species:ncbi:9606">patients</span>
###xml 1482 1490 <span type="species:ncbi:9606">patients</span>
###xml 1763 1771 <span type="species:ncbi:9606">patients</span>
###xml 1984 1992 <span type="species:ncbi:9606">patients</span>
As E148Q is one of the common mutations in Turkish patients with FMF, the screening of E148Q mutation in a healthy Turkish cohort also allowed us to determine the E148Q mutation carrier rate in the Turkish healthy population. The carrier frequency of the E148Q mutation has been reported to be 12% in Turkish population, the present study we found 12%, the frequency in Ashkenazi Jews is 10%, the frequency in Jews of Moroccan origin is 6.4%, and as high as 53% in Jews from the various ethnic groups [6, 9, 10]. Several authors have considered E148Q as a mild mutation [38, 39]. Askentijevich et al. has been proposed that E148Q is a polymorphism, not a disease causing mutation, and has a low penetrance [39]. In accordance with this hypothesis, healthy individuals have been found to be homozygous for the E148Q variation [6, 9, 39]. Yilmaz et al. showed that the distribution of the E148Q MEFV mutation among healthy individuals (E148Q 12%) was significantly different (P < 0.005) from that found in patients (E148Q 3.55%) [10]. They found 3.5% for E148Q carrier rate in patients group unlike our study. Tchernitchko et al. stated that the frequency of the E148Q allele was be similar in patients and healthy controls (3.62% and 3.75%, respectively, p = 0.93) [40]. Present study was showed that carrier frequencies were far higher among patients with FMF (19.1%) than among healthy carriers (12%). 11 of 36 E148Q compound heterozygotes (30.5%) were asymptomatic; the remaining patients had typical FMF attacks. Thus our results do not completely rule out the possibility that the E148Q mutation has an upregulating effect on inflammation in both FMF and other chronic inflammatory processes. We believe that symptomatic individuals who are E148Q carriers in patients group may be cosegregation with diseases causing unknown mutations in the east of Anatolia region. Thus, we planned a new study to detect of diseases causing unknown mutations by MEFV gene sequencing analysis in patients with E148Q compound heterozygotes and heterozygotes in our region.
###end p 31
###begin p 32
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R41">41</xref>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV </italic>
###xml 325 329 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R38">38</xref>
###xml 438 441 438 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R42"> 42</xref>
###xml 442 445 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R43"> 43</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R44">44</xref>
###xml 785 788 785 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R45"> 45</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R46">46</xref>
###xml 1072 1074 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R48">48</xref>
###xml 1168 1172 1168 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MEFV</italic>
###xml 1190 1198 1190 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNFRSF1A</italic>
###xml 1209 1214 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MVK, </italic>
###xml 1227 1232 1227 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CIAS1</italic>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R49">49</xref>
###xml 1641 1642 1641 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R4">4</xref>
###xml 1643 1646 1643 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R50"> 50</xref>
###xml 1739 1741 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R51">51</xref>
###xml 1742 1745 1742 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R52"> 52</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 981 989 <span type="species:ncbi:9606">patients</span>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
###xml 1249 1257 <span type="species:ncbi:9606">patients</span>
###xml 1492 1500 <span type="species:ncbi:9606">patients</span>
###xml 1675 1683 <span type="species:ncbi:9606">patients</span>
###xml 1765 1773 <span type="species:ncbi:9606">patients</span>
It became evident that FMF is not fully recessive and some heterozygous patients tend to have relatively mild disease, but the disease cannot be distinguished clinically from that in homozygous patients [41]. Initially, some investigators assumed that these patients harbor less common MEFV mutations on the second allele in MEFV, but a number of investigators have failed to detect when complete sequencing of the gene was performed [38, 42, 43]. Our results are highly consistent with the existence of a clinical phenotype among some patients heterozygous for FMF and, thus, have several important implications. First, in some cases, FMF can be viewed as a dominant condition with low penetrance. A few reports of families with seemingly dominant inheritance have been published [44, 45]. Second, these patients have other periodic fevers, such as TRAPS, HIDS, or cryopyrin-associated periodic syndromes (CAPS), cannot be completely excluded. A few recent reports have described patients who are compound heterozygotes for mutations in 2 known recurrent fever genes [46-48]. These patients were found to have 2 or more reduced penetrance mutations, such as E148Q in MEFV, R92Q or P46L in TNFRSF1A, V377I in MVK, and V198M in CIAS1. In some cases, patients presented with symptoms of both diseases or with a more severe disease, and their treatment was also compromised due to unknown gene interactions among mutations in the known recurrent fever genes [49]. Third, previous studies in FMF patients showed that the presence of modifying alleles in MICA and SAA are associated with a severe FMF phenotype and susceptibility to amyloidosis [4, 50]. Fourth, the proportion of patients with a single mutation varies between 16.5% and 33.8% [51, 52]. The frequency of patients with one mutations in present study were 40.2%. Single-mutation FMF may be much more common than has previously been thought. The detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.
###end p 32
###begin p 33
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R53">53</xref>
###xml 1315 1317 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R23">23</xref>
###xml 1500 1502 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R53">53</xref>
###xml 103 109 <span type="species:ncbi:9103">Turkey</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 441 447 <span type="species:ncbi:9103">Turkey</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 655 662 <span type="species:ncbi:9606">patient</span>
###xml 775 781 <span type="species:ncbi:9103">Turkey</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
###xml 883 889 <span type="species:ncbi:9103">Turkey</span>
###xml 923 931 <span type="species:ncbi:9606">patients</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
Papodopoulos et al. reported that the integrated knowledge of molecular genetics characterizing FMF in Turkey will facilitate the diagnosis and clinical decision especially in patients with atypical symptoms. For example, there are regions, such as the Aegean region, represented by Izmir, and territories where the majority of patients with FMF do not exhibit any MEFV mutations. This is totally the reverse in other cases, as Southeastern Turkey, where the presence of a MEFV mutation is obligatory to diagnose FMF. Turkish FMF patients are characterized by an increased genetic heterogeneity, explained by the intrapopulation differentiation [53]. Our patient group was more heterogeneous, because of the ethnic and cultural interactions in the east of Anatolia region of Turkey, than the patients group included the previous studies that were carried out in different regions of Turkey. It should be noted that the FMF patients in our study had a broad spectrum of mutations, which may reflect the intercultural interactions of the ancient ethnic groups who lived in the east of Anatolia. Thus, the regional origin should be regarded as a determining factor in tailoring the diagnosis of FMF in Turkish patients. Previously reported studies showed the importance of the region of residence on disease severity [23]. The different results of studies which carried out in different regions but in similar ethnic groups show us that regional studies are as important as ethnic origin-based studies [53].
###end p 33
###begin p 34
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R54">54</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R55">55</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R56">56</xref>
###xml 869 872 869 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="R57"> 57</xref>
###xml 406 412 <span type="species:ncbi:9606">people</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
###xml 715 721 <span type="species:ncbi:9103">Turkey</span>
###xml 823 829 <span type="species:ncbi:9103">Turkey</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
###xml 1050 1056 <span type="species:ncbi:9103">Turkey</span>
###xml 1287 1295 <span type="species:ncbi:9606">children</span>
###xml 1320 1328 <span type="species:ncbi:9606">patients</span>
Kelly et al. emphasize that genetic counseling is an educational process that seeks to assist affected and at-risk individuals to understand the nature of the genetic disorder, its transmission and the options open to them in the management of the disease and family planning [54]. Such knowledge can improve their understanding and eliminate wrong beliefs and conceptions about this disorder. Frequently, people have attributed their disease to the wrong cause, leading to unjustified guilt feelings [55]. It seems that close collaboration between the treating physician and the genetic counselor would be of great benefit and value to FMF patients and their families. The intermarriage rate differs regionally in Turkey. For example, the incidence of intermarriage in the east of Anatolia region and The Aegean region in Turkey were as 33% and 1.4%, respectively [56, 57]. Intermarriage between relatives may be increased the rate of diseases with autosomal recessive inheritance as FMF. Thus, we suggest that genetic counseling of FMF patients in Turkey should be different from other nations such as Turks, North African and Ashkenazi Jews, and Arabs because of the high incidence of intermarriage rate in the east of Anatolia. Firstly, we advise to get genetic testing done for the children and the spouses of such patients. Secondly, we recommend that all the intermarried couples with MEFV gene mutation carrier should be strongly monitor their future pregnancies by prenatal diagnosis to exclude the possibility of a homozygotes mutation carrier.
###end p 34
###begin p 35
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Our data imply that despite the heterogeneity, molecular diagnosis appear to be feasible in most patients, because a molecular diagnosis technique did not found MEFV gene mutation in only seven out of 415 patients. As we observed clinical heterogeneity and a high frequency of symptoms, our view is that symptomatic patients with heterozygote or negative patients with recurrent fevers and an increase in acute phase reactants during the attacks require colchicine treatment until as yet undetermined modifier genes or environmental factors are found, especially in the areas where the disease is prevalent. Those cases have to be detected as early as possible to arrange for treatment and adequate genetic counseling.
###end p 35
###begin p 36
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 138 144 <span type="species:ncbi:9103">Turkey</span>
###xml 693 699 <span type="species:ncbi:9103">Turkey</span>
###xml 797 803 <span type="species:ncbi:9103">Turkey</span>
In conclusion, this study allowed us establishing the spectrum of the MEFV mutations among FMF patients in the east of Anatolia region of Turkey. The most important features were the predominance of the M694V mutation and the low frequency of non-mutated alleles. The molecular analysis of the MEFV gene is the only objective test that confirms the diagnosis in our cohort. A genotype-phenotype correlation showed a relationship between the M694V mutation and the earlier of onset of the disease. Many ethnic groups live in Anatolia and more ethnic origin-based studies are needed to determine the real effect of these mutations. Our study also confirms the mutational heterogeneity of FMF in Turkey. In addition, different intermarriage rates may be one reason for different mutation profiles in Turkey.
###end p 36
###begin title 37
REFERENCES
###end title 37
###begin article-title 38
The French FMF Consortium. A candidate gene for familial mediterranean fever
###end article-title 38
###begin article-title 39
Criteria for the diagnosis of familial mediterranean fever
###end article-title 39
###begin article-title 40
Intermittent and periodic arthritis syndromes
###end article-title 40
###begin article-title 41
The MICA region determines the first modifier locus in familial mediterranean fever
###end article-title 41
###begin article-title 42
Familial Mediterranean Fever (FMF) and beyond: A new horizon. Fourth international congress on the systemic autoinflammatory diseases held in Bethesda
###end article-title 42
###begin article-title 43
Colchicine update
###end article-title 43
###begin article-title 44
Clinical differences between North African and Iraqi Jews with Familial Mediterranean Fever
###end article-title 44
###begin article-title 45
Common MEFV mutations among Jewish Ethnic groups in Israel: High frequency of carrier and phenotype iii states and absence of a perceptible biological advantage for the carrier state
###end article-title 45
###begin article-title 46
Higher than expected carrier rates for Familial Mediterranean Fever in various jewish ethnic groups
###end article-title 46
###begin article-title 47
Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population
###end article-title 47
###begin article-title 48
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Genotype-phenotype correlation in a large group of turkish patients with familial mediterranean fever: evidence for mutation-independent amyloidosis
###end article-title 48
###begin article-title 49
NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain
###end article-title 49
###begin article-title 50
A common pathway in periodic fever syndromes
###end article-title 50
###begin article-title 51
Targeted disruption of pyrin, the fmf protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis
###end article-title 51
###begin article-title 52
Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation
###end article-title 52
###begin article-title 53
Familial Mediterranean Fever. A survey of 470 cases and review of literature
###end article-title 53
###begin article-title 54
Familial Mediterranean Fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health
###end article-title 54
###begin article-title 55
Familial Mediterranean Fever in Armenians: autosomal recessive inheritance with high gene frequency
###end article-title 55
###begin article-title 56
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Megarbane, amyloidosis in Familial Mediterranean Fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects
###end article-title 56
###begin article-title 57
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Prevalence of ischemic heart disease in patients with familial Mediterranean fever
###end article-title 57
###begin article-title 58
Genetic testing for Familial Mediterranean Fever in Austria by means of reverse-hybridization teststrips
###end article-title 58
###begin article-title 59
Diagnosis of Familial Mediterranean Fever by a molecular genetic method
###end article-title 59
###begin article-title 60
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 87 93 <span type="species:ncbi:9103">Turkey</span>
MEFV mutations in patients with Familial Mediterranean Fever from the aegean region of Turkey
###end article-title 60
###begin article-title 61
Is MEFV gene Arg202GLN (605 G[A) A disease-causing mutation?
###end article-title 61
###begin article-title 62
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Analysis of Familial Mediterranean Fever gene mutations in 202 patients with familial mediterranean fever
###end article-title 62
###begin article-title 63
Comparison of the results of PCR-RFLP and reverse hybridization methods used in molecular diagnosis of FMF
###end article-title 63
###begin article-title 64
###xml 74 80 <span type="species:ncbi:9103">Turkey</span>
Familial Mediterranean Fever gene mutations in the southeastern region of Turkey and their phenotypical features
###end article-title 64
###begin article-title 65
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 88 94 <span type="species:ncbi:9103">Turkey</span>
MEFV mutations in patients with Familial Mediterranean Fever in The Black Sea Region of Turkey: Samsun experience [Corrected]
###end article-title 65
###begin article-title 66
Direct detection of common mutations in the Familial Mediterranean Fever gene by using PCR methods
###end article-title 66
###begin article-title 67
Diyarbakir Yoresi Ailevi Akdeniz Atesli Cocuklarda MEFV Gen Mutasyon Sikliklarn
###end article-title 67
###begin article-title 68
###xml 38 44 <span type="species:ncbi:9103">Turkey</span>
Familial Mediterranean Fever (FMF) in Turkey: The results of a nationwide multicenter study
###end article-title 68
###begin article-title 69
Familial Mediterranean Fever mutation frequencies and carrier rates among a mixed arabic population
###end article-title 69
###begin article-title 70
###xml 34 42 <span type="species:ncbi:9606">children</span>
Genotype-phenotype correlation in children with Familial Mediterranean Fever in a Turkish population
###end article-title 70
###begin article-title 71
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Familial Mediterranean Fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients
###end article-title 71
###begin article-title 72
Assessment of pyrin gene mutations in turks with Familial Mediterranean Fever (FMF)
###end article-title 72
###begin article-title 73
MEFV mutations in Familial Mediterranean Fever: Association of M694V hemozygosity with arthritis
###end article-title 73
###begin article-title 74
###xml 38 44 <span type="species:ncbi:9103">Turkey</span>
Familial Mediterranean Fever (FMF) in Turkey: Results of a nationwide multicenter study
###end article-title 74
###begin article-title 75
Non-founder mutations in the mefv gene establish this gene as the cause of Familial Mediterranean Fever (FMF)
###end article-title 75
###begin article-title 76
Mutational and haplotype studies in Familial Mediterranean Fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population
###end article-title 76
###begin article-title 77
The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever
###end article-title 77
###begin article-title 78
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Clinical and subclinical inflammation in patients with Familial Mediterranean Fever and in heterozygous carriers of MEFV mutations
###end article-title 78
###begin article-title 79
###xml 106 114 <span type="species:ncbi:9606">patients</span>
MEFV analysis is of particularly weak diagnostic value for recurrent fevers in western European Caucasian patients
###end article-title 79
###begin article-title 80
Familial Mediterranean Fever with a single MEFV mutation: Where is the second hit?
###end article-title 80
###begin article-title 81
The genetic basis of autosomal dominant familial Mediterranean fever
###end article-title 81
###begin article-title 82
A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual Familial Mediterranean Fever phenotype or another MEFV-associated periodic inflammatory disorder?
###end article-title 82
###begin article-title 83
Coexistent MEFV and CIAS1 mutations manifesting as Familial Mediterranean Fever plus deafness [letter]
###end article-title 83
###begin article-title 84
Familial autoinflammatory diseases: Genetics, pathogenesis and treatment
###end article-title 84
###begin article-title 85
Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations
###end article-title 85
###begin article-title 86
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Hyper IgD syndrome (HIDS) associatedwith in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept
###end article-title 86
###begin article-title 87
Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever
###end article-title 87
###begin article-title 88
###xml 81 89 <span type="species:ncbi:9606">patients</span>
A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients
###end article-title 88
###begin article-title 89
###xml 64 72 <span type="species:ncbi:9606">children</span>
Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever
###end article-title 89
###begin article-title 90
###xml 59 67 <span type="species:ncbi:9606">patients</span>
MEFV heterogeneity in Turkish Familial Mediterranean Fever patients
###end article-title 90
###begin article-title 91
Psychological aspects of genetic counseling. III. Management of guilt and shame
###end article-title 91
###begin article-title 92
###xml 49 55 <span type="species:ncbi:9103">Turkey</span>
Clinical outcomes of consanguineous marriages in Turkey
###end article-title 92
###begin article-title 93
Turkiye Nufus ve Saglik Arasturmasi TNSA Analiz ve Rapor, Hacettepe Universitesi Nufus Etutleri Enstitusu, Ankara
###end article-title 93
###begin p 94
###xml 31 39 <span type="species:ncbi:9606">Patients</span>
Phenotypic Features of 415 FMF Patients
###end p 94
###begin p 95
###xml 61 67 <span type="species:ncbi:9103">Turkey</span>
Distributions of Alleles in Studies of Different Groups from Turkey
###end p 95
###begin p 96
###xml 25 33 <span type="species:ncbi:9606">Patients</span>
Mutation Profiles of 415 Patients with FMF
###end p 96

